Phase II trial on Programmed death-One inhibitor plus RadioThERapy in patients with Metastatic Mucosal Melanoma
Latest Information Update: 06 Jan 2025
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PORTER-M3 trial
Most Recent Events
- 14 Sep 2018 Status changed from not yet recruiting to recruiting.
- 05 Mar 2018 New trial record